Pharmacotherapy of nasal disease.
Rhinitis may be classified as infectious (purulent), seasonal allergic, perennial allergic, perennial nonallergic (vasomotor) and nasal polyps. Pharmacotherapy can be local or systemic. A variety of compounds are available, including alpha adrenergic agonists, mast cell stabilizing agents, Beta-2 agonists, antihistamines, cholinergic antagonists and corticosteroids. In terms of histamine receptors, H1 receptors predominate in the epithelium and glands but both H1 and H2 receptors are present in nasal blood vessels. Trigeminus-reflex mediated nasal secretions, can be treated by parasympatholytic drugs.
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008407:Mast Cells / Q000187:drug effects; D009298:Nasal Polyps / Q000188:drug therapy; D010276:Parasympatholytics / Q000627:therapeutic use; D012220:Rhinitis / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D006634:Histamine H1 Antagonists; D010276:Parasympatholytics; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents